135 related articles for article (PubMed ID: 37801340)
21. Hematopoietic cell transplantation as treatment of patients with acute myeloid leukemia with measurable residual disease after consolidation therapy.
Appelbaum FR
Best Pract Res Clin Haematol; 2018 Dec; 31(4):405-409. PubMed ID: 30466757
[TBL] [Abstract][Full Text] [Related]
22. Impact of induction chemotherapy with intermediate-dosed cytarabine and subsequent allogeneic stem cell transplantation on the outcome of high-risk acute myeloid leukemia.
Fleischmann M; Schnetzke U; Frietsch JJ; Sayer HG; Schrenk K; Hammersen J; Glaser A; Hilgendorf I; Hochhaus A; Scholl S
J Cancer Res Clin Oncol; 2022 Jun; 148(6):1481-1492. PubMed ID: 34297206
[TBL] [Abstract][Full Text] [Related]
23. Detection of measurable residual disease may better predict outcomes than mutations based on next-generation sequencing in acute myeloid leukaemia with biallelic mutations of CEBPA.
Wang J; Lu R; Wu Y; Jia J; Gong L; Liu X; Lu S; Wang Y; Yan C; Liu K; Zhang X; Xu L; Jiang Q; Zhao X; Shi H; Lai Y; Huang X; Ruan G; Jiang H
Br J Haematol; 2020 Aug; 190(4):533-544. PubMed ID: 32090321
[TBL] [Abstract][Full Text] [Related]
24. Efficacy of conventional-dose cytarabine, idarubicin and thioguanine versus intermediate-dose cytarabine and idarubicin in the induction treatment of acute myeloid leukemia: Long-term results of the prospective randomized nationwide AML-2003 study by the Finnish Leukemia Group.
Kolonen A; Sinisalo M; Huhtala H; Rimpiläinen J; Rintala H; Sankelo M; Koivunen E; Silvennoinen R; Räty R; Ruutu T; Volin L; Porkka K; Jantunen E; Nousiainen T; Kuittinen T; Penttilä K; Pyörälä M; Säily M; Koistinen P; Kauppila M; Itälä-Remes M; Ollikainen H; Rauhala A; Kairisto V; Pelliniemi TT; Elonen E;
Eur J Haematol; 2022 Sep; 109(3):257-270. PubMed ID: 35634931
[TBL] [Abstract][Full Text] [Related]
25. Measurable Residual Disease at Induction Redefines Partial Response in Acute Myeloid Leukemia and Stratifies Outcomes in Patients at Standard Risk Without NPM1 Mutations.
Freeman SD; Hills RK; Virgo P; Khan N; Couzens S; Dillon R; Gilkes A; Upton L; Nielsen OJ; Cavenagh JD; Jones G; Khwaja A; Cahalin P; Thomas I; Grimwade D; Burnett AK; Russell NH
J Clin Oncol; 2018 May; 36(15):1486-1497. PubMed ID: 29601212
[TBL] [Abstract][Full Text] [Related]
26. Allogeneic Hematopoietic Cell Transplantation vs Standard Consolidation Chemotherapy in Patients With Intermediate-Risk Acute Myeloid Leukemia: A Randomized Clinical Trial.
Bornhäuser M; Schliemann C; Schetelig J; Röllig C; Kramer M; Glass B; Platzbecker U; Burchert A; Hänel M; Müller LP; Klein S; Bug G; Beelen D; Rösler W; Schäfer-Eckart K; Schmid C; Jost E; Lenz G; Tischer J; Spiekermann K; Pfirrmann M; Serve H; Stölzel F; Alakel N; Middeke JM; Thiede C; Ehninger G; Berdel WE; Stelljes M
JAMA Oncol; 2023 Apr; 9(4):519-526. PubMed ID: 36757706
[TBL] [Abstract][Full Text] [Related]
27. [Effect of consolidation before allogeneic hematopoietic stem cell transplantation for non-favorable acute myeloid leukemia patients with first complete remisson and negative minimal residual disease].
Zhang YM; Zhang Y; Ni X; Gao L; Qiu HY; Zhang YS; Tang GS; Chen J; Zhang WP; Wang JM; Yang JM; Hu XX
Zhonghua Xue Ye Xue Za Zhi; 2020 Jan; 41(1):16-22. PubMed ID: 32023749
[No Abstract] [Full Text] [Related]
28. NGS-defined measurable residual disease (MRD) after initial chemotherapy as a prognostic biomarker for acute myeloid leukemia.
Li Y; Solis-Ruiz J; Yang F; Long N; Tong CH; Lacbawan FL; Racke FK; Press RD
Blood Cancer J; 2023 Apr; 13(1):59. PubMed ID: 37088803
[TBL] [Abstract][Full Text] [Related]
29. Measurable residual disease in hematopoietic stem cell transplantation-eligible patients with acute myeloid leukemia: clinical significance and promising therapeutic strategies.
Gaut D; Mead M
Leuk Lymphoma; 2021 Jan; 62(1):8-31. PubMed ID: 33138674
[TBL] [Abstract][Full Text] [Related]
30. Minimal residual disease as biomarker for optimal biologic dosing of ARA-C in patients with acute myeloid leukemia.
Maurillo L; Buccisano F; Piciocchi A; Del Principe MI; Sarlo C; Di Veroli A; Panetta P; Irno-Consalvo M; Nasso D; Ditto C; Refrigeri M; De Angelis G; Cerretti R; Arcese W; Sconocchia G; Lo-Coco F; Amadori S; Venditti A
Am J Hematol; 2015 Feb; 90(2):125-31. PubMed ID: 25377359
[TBL] [Abstract][Full Text] [Related]
31. Measurable Residual Disease Assessment and Allogeneic Transplantation as Consolidation Therapy in Adult Acute Lymphoblastic Leukemia in Colombia.
Combariza JF; Arango M; Díaz L; Agudelo C; Hernandez S; Madera AM; León G; Avila V; Bautista L; Valdés J; Orduz R; Mejía F; Moreno L; Ramirez C
Clin Lymphoma Myeloma Leuk; 2021 Apr; 21(4):e365-e372. PubMed ID: 33277225
[TBL] [Abstract][Full Text] [Related]
32. [Minimal residual disease in adults with Philadelphia chromosome negative acute lymphoblastic leukemia in high-risk].
Li ZR; Zhao T; Liu YR; Wang YZ; Xu LP; Zhang XH; Wang Y; Jiang H; Chen YY; Chen H; Han W; Yan CH; Wang J; Jia JS; Huang XJ; Jiang Q
Zhonghua Xue Ye Xue Za Zhi; 2019 Jul; 40(7):554-560. PubMed ID: 32397017
[No Abstract] [Full Text] [Related]
33. Highlighting the Prognostic Importance of Measurable Residual Disease Among Acute Myeloid Leukemia Risk Factors.
Narlı Özdemir Z; Şahin U; Dalva K; Baltacı MA; Uslu A; Öztürk C; Cengiz Seval G; Toprak SK; Kurt Yüksel M; Topçuoğlu P; Arslan Ö; Özcan M; Beksaç M; İlhan O; Gürman G; Civriz Bozdağ S
Turk J Haematol; 2021 Jun; 38(2):111-118. PubMed ID: 33112099
[TBL] [Abstract][Full Text] [Related]
34. MRD-directed risk stratification treatment may improve outcomes of t(8;21) AML in the first complete remission: results from the AML05 multicenter trial.
Zhu HH; Zhang XH; Qin YZ; Liu DH; Jiang H; Chen H; Jiang Q; Xu LP; Lu J; Han W; Bao L; Wang Y; Chen YH; Wang JZ; Wang FR; Lai YY; Chai JY; Wang LR; Liu YR; Liu KY; Jiang B; Huang XJ
Blood; 2013 May; 121(20):4056-62. PubMed ID: 23535063
[TBL] [Abstract][Full Text] [Related]
35. Measurable residual disease monitoring by NGS before allogeneic hematopoietic cell transplantation in AML.
Thol F; Gabdoulline R; Liebich A; Klement P; Schiller J; Kandziora C; Hambach L; Stadler M; Koenecke C; Flintrop M; Pankratz M; Wichmann M; Neziri B; Büttner K; Heida B; Klesse S; Chaturvedi A; Kloos A; Göhring G; Schlegelberger B; Gaidzik VI; Bullinger L; Fiedler W; Heim A; Hamwi I; Eder M; Krauter J; Schlenk RF; Paschka P; Döhner K; Döhner H; Ganser A; Heuser M
Blood; 2018 Oct; 132(16):1703-1713. PubMed ID: 30190321
[TBL] [Abstract][Full Text] [Related]
36. Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia: Time to Move Toward a Minimal Residual Disease-Based Definition of Complete Remission?
Araki D; Wood BL; Othus M; Radich JP; Halpern AB; Zhou Y; Mielcarek M; Estey EH; Appelbaum FR; Walter RB
J Clin Oncol; 2016 Feb; 34(4):329-36. PubMed ID: 26668349
[TBL] [Abstract][Full Text] [Related]
37. Understanding differential technologies for detection of MRD and how to incorporate into clinical practice.
Cloos J; Ngai LL; Heuser M
Hematology Am Soc Hematol Educ Program; 2023 Dec; 2023(1):682-690. PubMed ID: 38066915
[TBL] [Abstract][Full Text] [Related]
38. Allogeneic hematopoietic stem cell transplantation could improve survival for pure CBF-AML patients with minimal residual disease positive after the second consolidation.
Wang T; Zhou B; Zhang J; Zhang X; Liu T; Qiu H; Sun A; Chen S; Wu D; Xu Y
Leuk Lymphoma; 2021 Apr; 62(4):995-998. PubMed ID: 33191833
[TBL] [Abstract][Full Text] [Related]
39. Activity of decitabine as maintenance therapy in core binding factor acute myeloid leukemia.
Senapati J; Shoukier M; Garcia-Manero G; Wang X; Patel K; Kadia T; Ravandi F; Pemmaraju N; Ohanian M; Daver N; DiNardo C; Alvarado Y; Aldrich J; Borthakur G
Am J Hematol; 2022 May; 97(5):574-582. PubMed ID: 35150150
[TBL] [Abstract][Full Text] [Related]
40. [Clinical Study on Dynamic Detection of Minimal Residual Disease in Acute Myeloid Leukemia by Multiparameter Flow Cytometry].
Jin Y; Wang AY; Wang XB; Yang HZ; Liu X
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Jun; 30(3):737-743. PubMed ID: 35680798
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
